Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin in Type 2 Diabetes with High Cardiovascular Risk (BEST)
NCT02558296Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- Oct 2015
- Primary completion
- Aug 2018
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Bexagliflozin 20 mg with Placebo (2 arms). Primary endpoint: Change in Hemoglobin A1c at 24 weeks. Started Oct 2015; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02558296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558296.